Shuwen Hu1, Zidi Xu, Jie Yan, Min Liu, Bing Sun, Wenjing Li, Yanmei Sang. 1. National Key Discipline of Pediatrics, Capital Medical University, Ministry of Education, Endocrine and Genetic Metabolic Center, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
Abstract
OBJECTIVE: To study the treatment effect and safety of diazoxide on patients with congenital hyperinsulinism (CHI). RESEARCH DESIGN AND METHODS: A total of 44 patients who have been hospitalized to our hospital and used diazoxide as a trial after diagnosis of CHI were chosen as research subjects. The clinical data of the patients were analyzed, and the treatment effects and safety of diazoxide on CHI were evaluated. RESULTS: In the 44 patients studied, the blood glucoses of 36 cases recovered to normal level after using diazoxide, indicating that the 36 patients respond to the treatment of diazoxide. Eight cases still showed severe hypoglycemia after using diazoxide for 10 days, which indicated that the eight patients were unresponsive to diazoxide treatment. Eighteen patients suffered the side effect of fluid retention, and 12 patients suffered transient gastrointestinal reactions. CONCLUSION: Diazoxide is a first-line treatment of CHI with high safety. Most of the patients with CHI were responsive to diazoxide treatment. Diazoxide should be used as a trial immediately after CHI diagnosis was made.
OBJECTIVE: To study the treatment effect and safety of diazoxide on patients with congenital hyperinsulinism (CHI). RESEARCH DESIGN AND METHODS: A total of 44 patients who have been hospitalized to our hospital and used diazoxide as a trial after diagnosis of CHI were chosen as research subjects. The clinical data of the patients were analyzed, and the treatment effects and safety of diazoxide on CHI were evaluated. RESULTS: In the 44 patients studied, the blood glucoses of 36 cases recovered to normal level after using diazoxide, indicating that the 36 patients respond to the treatment of diazoxide. Eight cases still showed severe hypoglycemia after using diazoxide for 10 days, which indicated that the eight patients were unresponsive to diazoxide treatment. Eighteen patients suffered the side effect of fluid retention, and 12 patients suffered transient gastrointestinal reactions. CONCLUSION:Diazoxide is a first-line treatment of CHI with high safety. Most of the patients with CHI were responsive to diazoxide treatment. Diazoxide should be used as a trial immediately after CHI diagnosis was made.
Authors: Keyaria D Gray; Kathryn Dudash; Carla Escobar; Colman Freel; Tylah Harrison; Chandler McMillan; Mihai Puia-Dumitrescu; C Michael Cotten; Robert Benjamin; Reese H Clark; Daniel K Benjamin; Rachel G Greenberg Journal: J Perinatol Date: 2018-09-11 Impact factor: 3.225